Welcome to Team Genus
Asset Allocation & Portfolio Management Tools for Investors
 
  • Welcome : Guest
  • Icon
 
About Team Genus Post your feedback Client Registration
Your Current Location : Fund Card : Fund Summary
 
Nippon India Pharma Fund IDCW Direct
[Equity: Sectoral]
Other Options
 
Fund Details
Fund Type Dividend Launch Date 14 Jan 2013
Corpus(Cr.) 8689.0 Scheme NAV 179.728
Equity(%) 95.6 52 Week High 187.892
Debt(%) 4.4 52 Week Low 139.357
Others(%) 0.0 Exit Load 1% for redemption within 30 days
Minimum Investment - Availability Open
Entry Load - Expense Ratio(%) 0.91
Scheme Benchmark BSE Healthcare TRI Broader Benchmark NSE - Nifty 50 TRI
 
Scheme Objective
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
 
Last 10 Dividends
Date of Dividend Declaration Dividend (Individual) Per Unit(Rs.) Dividend (Corporate) Per Unit(Rs.)
23-02-2024 10.00 10.00
25-02-2022 3.50 3.50
26-02-2021 6.00 6.00
28-02-2020 3.98 3.98
01-03-2019 4.43 4.43
01-03-2018 6.00 6.00
 
 
 
useful links Reserve Bank of India
 
FUNDS : 360  |  Aditya  |  Axis  |  Bajaj  |  Bandhan  |  Bank  |  Baroda  |  Canara  |  DSP  |  Edelweiss  |  Edelweiss  |  Franklin  |  Groww  |  HDFC  |  Helios  |  HSBC  |  ICICI  |  Invesco  |  ITI  |  JM  |  Kotak  |  LIC  |  Mahindra  |  Mirae  |  Motilal  |  NAVI  |  Nippon  |  NJ  |  Old  |  PGIM  |  PPFAS  |  Quant  |  Quantum  |  Samco  |  SBI  |  Shriram  |  Sundaram  |  Tata  |  Taurus  |  TRUST  |  Union  |  User  |  UTI  |  WhiteOak  |  Zerodha  | 
 

Disclaimer: While all efforts have been taken to make this web site as authentic as possible, Team Genus Financial Services Private Limited (www.teamgenus.in) will not be responsible for any loss to any person/entity caused by any short-coming; defect or inaccuracy inadvertently or otherwise crept in the teamgenus.in web site. Mutual Fund Investments are subject to market risks, read all scheme related documents carefully before investing into Mutual Funds. The use of information and services is subject to the terms and conditions governing this website.

Follow Us on
Design & Developed by : InvestWell